Ajanta Pharmaceuticals quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	1,626	1,303	+24.8%
EBITDA	424	351	+20.6%
EBITDA margin	26.1%	27.0%	−0.9 pts
Profit before tax	447	331	+34.9%
Net profit	334	255	+30.9%
EPS	₹26.75	₹20.44	+30.9%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	1,626	1,422	1,375	1,354	1,303	1,170	1,146	1,187	1,145	1,054	1,105	1,028	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	70.9	61.4	25.0	59.3	26.3	18.1	30.4	19.5	26.5	35.5	13.6	21.3
	1,697	1,483	1,400	1,413	1,329	1,189	1,177	1,206	1,171	1,090	1,119	1,050
	297	257	235	218	207	191	210	207	238	259	239	224
	66.9	71.4	53.6	53.3	51.6	80.2	78.6	45.8	45.3	40.4	39.3	47.0
	−35.6	−23.3	−2.4	46.0	17.2	12.3	−30.9	8.8	−15.8	−35.1	15.8	−14.4
	381	341	331	317	303	280	265	261	284	234	231	222
	3.2	2.4	5.1	3.4	5.3	6.1	7.9	6.0	0.7	1.5	2.5	2.3
	44.5	45.4	43.5	43.0	41.3	39.8	36.0	34.4	34.0	34.3	34.3	33.7
	493	443	376	392	373	310	302	353	263	278	266	259
	1,250	1,136	1,041	1,072	998	919	869	916	849	812	828	774
	424	333	382	328	351	297	321	311	330	278	314	291
	379	288	339	285	310	257	285	277	296	244	280	257
Profit
	447	347	359	341	331	269	307	290	322	278	291	276
	447	347	359	341	331	269	307	290	322	278	291	276
	103	61.4	86.9	78.3	73.5	62.0	94.9	76.1	79.4	73.1	91.3	89.3
	9.9	19.0	−2.1	2.3	2.3	−17.8	−20.3	−2.4	−3.0	2.2	−10.4	−8.7
	113	80.4	84.8	80.6	75.8	44.2	74.5	73.8	76.4	75.3	80.9	80.6
	334	267	274	260	255	225	233	216	246	203	210	195
	334	267	274	260	255	225	233	216	246	203	210	195
	−4.3	18.1	2.5	8.3	0.2	2.0	1.4	5.7	−7.3	−6.4	2.8	7.1
	330	285	276	268	256	227	234	222	238	196	213	202
	330	267	274	260	255	225	233	216	238	196	210	195
Per share
	₹26.75	₹21.35	₹21.91	₹20.83	₹20.44	₹18.00	₹18.60	₹17.27	₹19.54	₹16.10	₹16.68	₹15.51
	₹26.72	₹21.34	₹21.91	₹20.82	₹20.43	₹18.00	₹18.59	₹17.26	₹19.53	₹16.09	₹16.67	₹15.50
Other comprehensive income — detail
	−4.3	18.1	2.5	8.3	0.2	2.0	—	—	—	—	—	—
	−5.1	3.5	0.3	0.7	−5.0	−2.2	−0.6	−2.4	−3.7	−1.4	−0.9	−0.6
	−1.8	1.2	0.1	0.3	−1.7	−0.8	—	—	—	—	—	—
	—	—	—	—	—	—	−0.2	−0.8	−1.3	−0.5	−0.3	−0.2
	−0.9	15.8	2.3	7.8	3.4	3.5	1.9	7.3	−4.9	−5.5	3.3	7.5
	330	285	276	268	256	227	234	222	—	—	—	—
Per share — as-filed variants
	₹26.75	₹21.35	₹21.91	₹20.83	₹20.44	₹18.00	₹18.60	₹17.27	₹19.54	₹16.10	₹16.68	₹15.51
	₹26.72	₹21.34	₹21.91	₹20.82	₹20.43	₹18.00	₹18.59	₹17.26	₹19.53	₹16.09	₹16.67	₹15.50
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,298	1,117	1,089	1,037	1,027	887	888	925	877	790	811	772
	79.8%	78.6%	79.2%	76.6%	78.8%	75.8%	77.5%	77.9%	76.6%	74.9%	73.4%	75.1%
Adjusted (ex-exceptional items) — derived
	447	347	359	341	331	269	307	290	322	278	291	276
	334	267	274	260	255	225	233	216	246	203	210	195
	₹26.75	₹21.35	₹21.91	₹20.83	₹20.44	₹18.00	₹18.60	₹17.27	₹19.54	₹16.10	₹16.68	₹15.51

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AJANTPHARM₹3,459.80

Ajanta Pharmaceuticals Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersALKEM IPCALAB TORNTPHARM ABBOTINDIA ANTHEM GLAXO MEDANTA GLENMARKMcap ₹43,369 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	1,028.4	1,105.2	1,054.1	1,144.9	1,186.6	1,146.1	1,170.4	1,302.7	1,353.7	1,374.8	1,421.6	1,626.0
Other Income	21.3	13.6	35.5	26.5	19.5	30.4	18.1	26.3	59.3	25.0	61.4	70.9
Total Income	1,049.8	1,118.7	1,089.6	1,171.4	1,206.1	1,176.6	1,188.5	1,329.0	1,413.1	1,399.8	1,483.1	1,696.9
Expenses
+ Cost of Materials Consumed	223.5	239.1	259.0	238.4	207.1	210.1	191.0	207.1	217.6	235.1	256.8	296.5
+ Purchases of Stock-in-Trade	47.0	39.3	40.4	45.3	45.8	78.6	80.2	51.6	53.3	53.6	71.4	66.9
+ Changes in Inventories	-14.4	15.8	-35.1	-15.8	8.8	-30.9	12.3	17.2	46.0	-2.4	-23.3	-35.6
+ Employee Benefit Expense	222.3	231.4	233.5	283.8	261.0	265.2	279.8	302.9	317.0	330.5	340.7	381.1
+ Finance Costs	2.3	2.5	1.5	0.7	6.0	7.9	6.1	5.3	3.4	5.1	2.4	3.2
+ Depreciation & Amortisation	33.7	34.3	34.3	34.0	34.4	36.0	39.8	41.3	43.0	43.5	45.4	44.5
+ Other Expenses	259.4	265.6	277.9	262.9	352.8	302.3	310.1	372.5	392.1	375.8	442.7	493.4
Total Expenses	773.8	827.8	811.5	849.3	915.9	869.2	919.1	997.9	1,072.3	1,041.2	1,136.0	1,250.1
EBITDA	290.7	314.1	278.3	330.4	311.2	320.8	297.2	351.4	327.8	382.2	333.4	423.6
EBIT	257.0	279.8	244.1	296.4	276.8	284.9	257.4	310.1	284.9	338.7	288.0	379.1
Profit
PBT before Exceptional Items	275.9	290.9	278.0	322.1	290.2	307.4	269.4	331.1	340.8	358.6	347.1	446.8
Pretax Income	275.9	290.9	278.0	322.1	290.2	307.4	269.4	331.1	340.8	358.6	347.1	446.8
+ Current Tax	89.3	91.3	73.1	79.4	76.1	94.9	62.0	73.5	78.3	86.9	61.4	102.7
+ Deferred Tax	-8.7	-10.4	2.2	-3.0	-2.4	-20.3	-17.8	2.3	2.3	-2.1	19.0	9.9
Tax Expense	80.6	80.9	75.3	76.4	73.8	74.5	44.2	75.8	80.6	84.8	80.4	112.6
Net Income	195.3	210.0	202.7	245.8	216.5	232.9	225.3	255.3	260.2	273.8	266.7	334.2
+ Net Income — Continuing Ops	195.3	210.0	202.7	245.8	216.5	232.9	225.3	255.3	260.2	273.8	266.7	334.2
+ Other Comprehensive Income	7.1	2.8	-6.4	-7.3	5.7	1.4	2.0	0.2	8.3	2.5	18.1	-4.3
Total Comprehensive Income	202.4	212.8	196.3	238.4	222.2	234.3	227.3	255.5	268.5	276.3	284.8	330.0
Net Income to Common	195.3	210.0	196.3	238.4	216.5	232.9	225.3	255.3	260.2	273.8	266.7	330.0
Per Share
Basic EPS	15.51	16.68	16.10	19.54	17.27	18.60	18.00	20.44	20.83	21.91	21.35	26.75
Diluted EPS	15.50	16.67	16.09	19.53	17.26	18.59	18.00	20.43	20.82	21.91	21.34	26.72
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	2.0	0.2	8.3	2.5	18.1	-4.3
+ Items NOT to be Reclassified to P&L	-0.6	-0.9	-1.4	-3.7	-2.4	-0.6	-2.2	-5.0	0.7	0.3	3.5	-5.1
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.8	-1.7	0.3	0.1	1.2	-1.8
+ Tax on Items NOT to be Reclassified — alt tag	-0.2	-0.3	-0.5	-1.3	-0.8	-0.2	—	—	—	—	—	—
+ Items to be Reclassified to P&L	7.5	3.3	-5.5	-4.9	7.3	1.9	3.5	3.4	7.8	2.3	15.8	-0.9
Comprehensive Income — Owners of Parent	—	—	—	—	222.2	234.3	227.3	255.5	268.5	276.3	284.8	330.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	15.51	16.68	16.10	19.54	17.27	18.60	18.00	20.44	20.83	21.91	21.35	26.75
Diluted EPS — Continuing Operations	15.50	16.67	16.09	19.53	17.26	18.59	18.00	20.43	20.82	21.91	21.34	26.72
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	772.3	811.0	789.7	877.1	925.0	888.3	887.0	1,026.8	1,036.9	1,088.6	1,116.8	1,298.1
Gross Margin %	75.10	73.38	74.92	76.61	77.95	77.51	75.78	78.82	76.60	79.18	78.56	79.84
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	275.9	290.9	278.0	322.1	290.2	307.4	269.4	331.1	340.8	358.6	347.1	446.8
Net Income Adj (tax-effected)	195.3	210.0	202.7	245.8	216.5	232.9	225.3	255.3	260.2	273.8	266.7	334.2
EPS Adj	15.51	16.68	16.10	19.54	17.27	18.60	18.00	20.44	20.83	21.91	21.35	26.75
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	25.3	25.3	25.3	25.1	25.1	25.1	25.1	25.1	25.1	25.1	25.1	25.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Ajanta Pharmaceuticals Q2 FY27 results date

Ajanta Pharmaceuticals (NSE: AJANTPHARM) will announce its Q2 FY27 results (July–September 2026) on Friday, 30 October 2026, according to the board-meeting notice it filed on 15 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹330 crore, up 29.2% from ₹255 crore in Q1 FY26 and up 23.7% from ₹267 crore in Q4 FY26. Revenue from operations was ₹1,626 crore, up 24.8% year on year and up 14.4% from the previous quarter.

Board-meeting notice filed: 15 October 2026
Q2 FY26 results (a year earlier): 3 November 2025
Q1 FY27 results (the latest): 30 July 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 30 October 2026Friday · notice filed 15 Oct
Q1 FY27 net profit: ₹330 Cr+29.2% vs Q1 FY26+23.7% vs Q4 FY26
Q1 FY27 revenue: ₹1,626 Cr+24.8% vs Q1 FY26+14.4% vs Q4 FY26
Q1 FY27 operating margin: 23.3%−0.5 pts vs Q1 FY26+3.1 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹260 CrRevenue ₹1,354 Cr
Q1 FY27 EPS (basic): ₹26.75

Questions

When will Ajanta Pharmaceuticals announce its Q2 FY27 results?

On 30 October 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 15 October 2026). Last year it reported Q2 FY26 on 3 November 2025.

What will Ajanta Pharmaceuticals' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹260 crore and revenue from operations ₹1,354 crore. The latest quarter, Q1 FY27, had a net profit of ₹330 crore and revenue of ₹1,626 crore.

What was Ajanta Pharmaceuticals' revenue in FY26?

Revenue from operations was ₹5,453 crore in FY26 (April 2025–March 2026), up 17.3% from ₹4,648 crore in FY25. It was ₹4,209 crore in FY24 and ₹3,743 crore in FY23: up 45.7% over three years, 13.4% a year on average.

What were Ajanta Pharmaceuticals' Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹330 crore, up 29.2% from ₹255 crore in Q1 FY26 and up 23.7% from ₹267 crore in Q4 FY26. Revenue from operations was ₹1,626 crore, up 24.8% year on year and up 14.4% from the previous quarter.

How has Ajanta Pharmaceuticals' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹260 crore in Q2 FY26, ₹274 crore in Q3 FY26, ₹267 crore in Q4 FY26 and ₹330 crore in Q1 FY27. That is ₹1,131 crore over the four quarters, up 21.6% from ₹930 crore in the four quarters before. Revenue from operations: ₹1,354 crore, ₹1,375 crore, ₹1,422 crore and ₹1,626 crore.

What was Ajanta Pharmaceuticals' net profit in FY26?

Consolidated net profit attributable to shareholders was ₹1,056 crore in FY26 (April 2025–March 2026), up 14.7% from ₹920 crore in FY25. It was ₹817 crore in FY24 and ₹588 crore in FY23: up 79.6% over three years, 21.6% a year on average.

Where do these Ajanta Pharmaceuticals figures come from?

From Ajanta Pharmaceuticals' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.